ESC Premium Access

Acute safety and performance outcomes from the inspIRE trial using a novel pulsed field ablation system for the treatment of paroxysmal atrial fibrillation

Congress Session

About the speaker

Doctor Tom De Potter

Cardiovascular Research Center Aalst, Aalst (Belgium)
23 presentations
0 follower

4 more presentations in this session

Long-term outcome of endocardial-only versus combined endocardial-epicardial homogenization of the scar for treatment of ventricular tachycardia in patients with ischemic cardiomyopathy

Speaker: Doctor S. Mohanty (Austin, US)

Thumbnail

Mutation in a non-desmosomal gene is associated with poor outcome of endo-epicardial ventricular tachycardia ablation in patients with nonischaemic cardiomyopathy

Speaker: Associate Professor P. Peichl (Prague, CZ)

Thumbnail

High precision machine learning-enabled ECG algorithm for predicting sites of idiopathic ventricular arrhythmia origin

Speaker: Mr J. Zheng (Orange, US)

Thumbnail

Recovery of conduction following high power short duration approach in radiofrequency catheter ablation for atrial fibrillation: a single-center experience

Speaker: Doctor S. Mohanty (Austin, US)

Thumbnail

Access the full session

Novel approaches to catheter ablation

Speakers: Doctor T. De Potter, Doctor S. Mohanty, Associate Professor P. Peichl, Mr J. Zheng, Doctor S. Mohanty
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

EHRA Premium Access

Comparison of safety and efficacy between POLARx and Arctic Front cryoballoon ablation

4 April 2022

EHRA Premium Access

Biophysical parameters and time to isolation of pulmonary veins with a novel cryoballoon: results of POLAR ICE study

3 April 2022

EHRA Premium Access

Selective epicardial pulsed field ablation of atrial ganglionated plexi causes anti-arrhythmic prolongation of refractoriness: demonstration of feasibility in cardiac surgery patients

3 April 2022

This platform is supported by

logo Novo Nordisk